Cannabidiol, the non-psychotropic compound found in cannabis, is drawing renewed attention as a potential multi-target therapy for Alzheimer’s disease, but a new review concludes that the evidence, while encouraging, does not yet support calling it a disease-modifying treatment.
The review, published in Molecular Biology Reports, was authored by Sreenivasulu Sura, Saravanan Jagadeesan, Siti Saleha Masrudin, Mohamad Aris Mohd Moklas and Nurul Huda Mohd Nor. It weighs the preclinical literature on cannabidiol, or CBD, across the major pathological domains of Alzheimer’s disease, a progressive neurodegenerative disorder in which amyloid-beta accumulation, tau dysregulation, neuroinflammation, oxidative stress, mitochondrial dysfunction, synaptic loss and neurodegeneration interact to drive memory loss and cognitive decline.
The authors argue that despite advances in symptomatic therapies and anti-amyloid agents, clinical benefit in Alzheimer’s disease remains modest, which has fuelled interest in polypharmacological approaches capable of acting on several disease mechanisms at once. CBD is attractive in this respect because it interacts with multiple signalling systems relevant to the disease, including cannabinoid-related pathways, the nuclear receptor PPARγ, TRPV1 channels, 5-HT1A signalling, fatty acid-binding proteins involved in anandamide transport, GPR55 and adenosine transporters.
On the strength of the available preclinical data, the most consistent findings are that CBD attenuates neuroinflammatory and oxidative responses and improves selected behavioural outcomes in laboratory models. These anti-inflammatory and antioxidant effects emerge as the strongest and most reproducible threads in the literature the review examined.
The picture is more mixed for other mechanisms. Evidence that CBD affects amyloid-related pathology is described as supportive but heterogeneous, with studies varying in the models, doses and outcome measures they employ. Direct evidence for tau modulation has expanded in transgenic and chemically induced models, but the authors stress that these findings remain model-dependent, meaning that results in one experimental system cannot be assumed to transfer to another.
Two further areas are judged less firmly established: mitochondrial rescue and the stimulation of adult hippocampal neurogenesis. The review indicates that while both effects have been reported, they lack the weight of evidence accumulated for the inflammatory and oxidative endpoints, and should be treated as hypotheses requiring further testing rather than settled conclusions.
A recurring theme is methodological variability. Differences in CBD source, formulation, dose, route of administration, treatment window, the sex and age of animals, and the choice of outcome measures limit direct comparison between studies. This heterogeneity makes it difficult to build a coherent dose-response picture or to identify which mechanisms are most robustly engaged in vivo, and the authors call for standardized, mechanism-focused and translationally relevant designs in future work.
The review also places CBD in the broader context of cannabinoid research, discussing work on other cannabinoids and on CBD combined with delta-9-THC. However, it is explicit that current evidence does not establish CBD as a disease-modifying treatment for Alzheimer’s disease, and no clinical efficacy claims are made.
The overall verdict is that preclinical evidence supports continued investigation of CBD as a multi-target neuroprotective candidate, provided that future studies address the methodological inconsistencies that currently hamper the field. The review identifies translational research priorities aimed at moving the most promising findings toward rigorous testing, while cautioning that the gap between laboratory models and human disease remains the central challenge for this line of research.
Subject of Research: Preclinical evidence for cannabidiol as a multi-target candidate therapy in Alzheimer's disease
Article Title: Cannabidiol in Alzheimer’s disease: evidence-weighted molecular mechanisms and translational challenges
Article References: Sura, S., Jagadeesan, S., Masrudin, S. S., Moklas, M. A. M., & Nor, N. H. M. (2026). Cannabidiol in Alzheimer’s disease: evidence-weighted molecular mechanisms and translational challenges. Molecular Biology Reports, 53(1), Article 1792. https://doi.org/10.1007/s11033-026-13034-9
Image Credits: AI Generated
DOI: 10.1007/s11033-026-13034-9
Keywords: cannabidiol, Alzheimer's disease, neuroinflammation, oxidative stress, tau, amyloid-beta, preclinical research, neuroprotection, PPARγ, translational research, phytocannabinoid, mitochondrial dysfunction
News Source: Cassandra Pierce. (October 29, 2026). Cannabidiol shows preclinical promise against Alzheimer’s disease, but key evidence gaps remain. Scienmag.
